Deal Library / Pharma BD Deal Intelligence

Ophthalmology Deals

The Pharma Closeout tracks 15 deals, $29.0B in disclosed deal value, 10 with a post-close Outcome Score for Ophthalmology.

Median Critic Score: 74 · Median Outcome Score: 49

All 15 deals

Johnson & Johnson / Abbott Medical Optics — 2003 · $4.3B · Largely worked — most objectives met.
Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) — 2016 · $4.3B · Largely worked — most objectives met.
Merck & Co. Inc. / EyeBio Ltd. — 2024 · $3.0B · Largely worked — most objectives met.
Viatris / Oyster Point Pharma, Inc. — 2022 · $299M · Mixed — partial payoff, real shortfalls.
Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. — 2026 · Mixed — partial payoff, real shortfalls.
EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) — 2000 · $32M · Mixed — partial payoff, real shortfalls.
Astellas Pharma Inc. / Ocata Therapeutics, Inc. — 2015 · $379M · Underwhelmed — fell short of the thesis.
Valeant Pharmaceuticals International Inc. / Bausch + Lomb — 2013 · $8.7B · Underwhelmed — fell short of the thesis.
Allergan plc / Oculeve, Inc. — 2015 · $250M · Underwhelmed — fell short of the thesis.
Merck & Co. Inc. / Inspire Pharmaceuticals, Inc. — 2011 · $430M · Did not work — the deal failed to deliver.
MeiraGTx Holdings plc / Johnson & Johnson (Janssen Pharmaceuticals) — 2026 · $25M
Eli Lilly and Company / Adverum Biotechnologies, Inc. — 2025 · $261M
Biogen Inc. / Nightstar Therapeutics plc — 2019 · $800M
Novartis AG / Xiidra (lifitegrast) from Takeda — 2019 · $5.3B
Auxilium Pharmaceuticals, Inc. / QLT Inc. — 2014 · $850M